Q32 Bio Inc
$ 5.72
-6.08%
16 Apr - close price
- Market Cap 83,681,000 USD
- Current Price $ 5.72
- High / Low $ 6.24 / 5.62
- Stock P/E 2.36
- Book Value 3.27
- EPS 2.42
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.14 %
- ROE 1.25 %
- 52 Week High 8.04
- 52 Week Low 1.34
About
Q32 Bio Inc. (QTTB) is an innovative biotechnology company specializing in the development of cutting-edge antibody-based therapies aimed at treating autoimmune diseases and optimizing immune responses. With its proprietary technology platform, Q32 Bio is advancing a diverse pipeline of therapeutic candidates poised to restore immune balance and address critical unmet medical needs. Supported by a highly experienced management team and strategic partnerships, Q32 Bio is strategically positioned to drive meaningful advancements in healthcare, ultimately creating long-term value for shareholders through its commitment to ongoing research and development excellence.
Analyst Target Price
$14.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-10 | 2025-11-13 | 2025-08-06 | 2025-05-07 | 2025-03-11 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-14 | 2023-08-14 | 2023-05-11 |
| Reported EPS | 4.58 | -0.6 | -0.78 | -0.9 | -1.16 | -1.457 | -1.42 | -14.95 | -0.28 | -0.57 | -0.61 | -0.5 |
| Estimated EPS | -0.86 | -1.19 | -0.8 | -1.23 | -1.53 | -1.4 | -1.04 | -2.32 | -0.3 | -0.43 | -0.5 | -0.52 |
| Surprise | 5.44 | 0.59 | 0.02 | 0.33 | 0.37 | -0.057 | -0.38 | -12.63 | 0.02 | -0.14 | -0.11 | 0.02 |
| Surprise Percentage | 632.5581% | 49.5798% | 2.5% | 26.8293% | 24.183% | -4.0714% | -36.5385% | -544.3966% | 6.6667% | -32.5581% | -22% | 3.8462% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.52 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QTTB
2026-04-08 18:10:09
Q32 Bio Inc. (Nasdaq: QTTB) announced its management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 12:45 p.m. E.T. The clinical-stage biotechnology company focuses on developing therapies for alopecia areata and other autoimmune diseases, with a webcast of the presentation available on their website. They are advancing bempikibart for alopecia areata in an ongoing Phase 2 program.
2026-04-08 11:39:07
Q32 Bio Inc. announced it will participate in the 25th Annual Needham Virtual Healthcare Conference. The company is set to host a fireside chat on Wednesday, April 15 at 12:45 p.m. ET, providing a webcast for participants. This engagement follows the release of its fourth-quarter 2025 financial results and corporate update, aiming to connect with the healthcare investment community.
2026-04-08 10:40:14
Q32 Bio Inc. announced that its management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 12:45 p.m. E.T. A webcast of the presentation will be available on the company's website, with an archived replay accessible for 90 days following the event. Q32 Bio is a clinical-stage biotechnology company focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases.
2026-04-08 10:39:07
Q32 Bio will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 12:45 p.m. ET. A live webcast will be available, with an archived replay accessible for 90 days. Despite the neutral conference news, QTTB's stock declined by 7.97% following the announcement, reflecting a negative market reaction.
2026-04-08 10:39:07
Q32 Bio Inc., a clinical-stage biotechnology company, announced its management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company is focused on developing therapies for autoimmune and inflammatory diseases, particularly alopecia areata, with its lead candidate bempikibart (ADX-914) in a Phase 2 program. Q32 Bio communicates investor information through its website, SEC filings, press releases, and social media channels.
2026-04-08 06:39:19
Q32 Bio Inc. (Nasdaq: QTTB), a clinical-stage biotechnology company, announced its participation in the 25th Annual Needham Virtual Healthcare Conference. The company's management will hold a fireside chat on April 15, 2026, at 12:45 p.m. E.T. Q32 Bio focuses on developing therapies for autoimmune and inflammatory diseases, including alopecia areata, with its lead candidate bempikibart (ADX-914) currently in a Phase 2 program.
